Antev Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Private
- Established
- 2008-09-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.antev.co.uk
Clinical Trials
3
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)Teverelix Evaluated in Advanced Prostate Cancer
Phase 2
Completed
- Conditions
- Prostatic Adenoma
- Interventions
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Antev Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04693507
- Locations
- 🇱🇹
Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania
🇱🇹Klaipeda University Hospital, Klaipeda, Lithuania
🇱🇹National Cancer Institute, Vilnius, Lithuania
A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Antev Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03781947
- Locations
- 🇬🇧
PAREXEL International Early Phase Clinical Unit (EPCU), London, Middlesex, United Kingdom
News
No news found